Skip to main content
Premium Trial:

Request an Annual Quote

LifeGen Tech Nets $124K SBIR Grant to Fund Array-Based Caloric-Restriction Study


By Justin Petrone

The National Institutes of Health has awarded LifeGen Technologies a Small Business Innovation Research grant to develop a genetic panel that can be used to screen for compounds related to fat tissue and diet, the company said last week.

Madison, Wis.-based LifeGen will use gene-expression arrays to identify genes in adipose tissue that are regulated by a calorie-restricted diet. The one-year, $123,895 grant from the National Institute of Aging began Sept. 1.

LifeGen will use its array platform to screen for compounds that have beneficial effects on adipose tissue in a manner similar to that of a calorie-restricted diet. Caloric restriction is the "only dietary intervention proven to increase both maximum and average lifespan in mammals, as well delaying age-related diseases," LifeGen said in a statement. "Because caloric restriction reduces body fat and markers of inflammation related to disease, it is thought that metabolic alterations in fat may underlie many of the health benefits associated with this dietary intervention."

The grant "clearly validates the enormous potential of LifeGen's technology in discovering the next generation of anti-aging compounds, based on caloric restriction science," LifeGen Co-founder and Chief Scientific Officer Tomas Prolla said.

LifeGen was founded in 2000 by Prolla and Richard Weindruch, both professors at the University of Wisconsin-Madison. The company uses its gene-expression array platform, which it licensed from the university, to study how the aging process is retarded by caloric restriction.

Company officials did not respond to an e-mail seeking additional comment in time for this publication.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.